Sign up
Pharma Capital

CytoDyn files for fast-track designation for leronlimab in breast cancer treatment

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive Investors the biotechnology company filed an application with the FDA seeking fast-track designation for its injectable antibody leronlimab for patients with metastatic-triple negative breast cancer.

Pourhassan also commented on its HIV indication for leronlimab, commenting there is a large biological manufacturer willing to produce 'half a billion dollars worth' of the company's product by the end of 2020.


View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.